Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)β’ Click on a phase to view related trials
A Study of K-645 in the Treatment of Multiple Migraine Attacks
- Conditions
- Acute Migraine
- Interventions
- Drug: PlaceboDrug: K-645 dose level 1Drug: K-645 dose level 2
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT07116499
- Locations
- πΊπΈ
Excell Research, Inc., Oceanside, California, United States
πΊπΈDelRicht Research - Atlanta, Atlanta, Georgia, United States
πΊπΈClinical Research Atlanta - Stockbridge, Stockbridge, Georgia, United States
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
- Conditions
- Acute Migraine
- Interventions
- Drug: Elismetrep (K-304) Dose Level 1Drug: Elismetrep (K-304) Dose level 2Drug: Elismetrep (K-304) Dose level 3Drug: Elismetrep (K-304) Dose level 4Drug: Placebo
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 431
- Registration Number
- NCT06848075
- Locations
- πΊπΈ
Central Research Associates, LLC (CRA) dba Flourish Research, Birmingham, Alabama, United States
πΊπΈAMR Mobile, Mobile, Alabama, United States
πΊπΈWake Research/ Tucson Neuroscience Research, Tucson, Arizona, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Obesity
- Interventions
- Drug: Matching placebo to K-757 and K-833 QDDrug: K-757 and K-833 QDDrug: Matching placebo to K-757 and K-833 BIDDrug: K-757 and K-833 BID
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT06305351
- Locations
- πΊπΈ
QPS Miami, Miami, Florida, United States
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
- Conditions
- Obesity
- Interventions
- Drug: K-757 120 mg BID and K-833 100 mg BIDDrug: K-757 120 mg BID and matching placebo to K-833Drug: Matching placebo to K-757 and matching placebo to K-833
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT06019559
- Locations
- πΊπΈ
Artemis Institute for Clinical Research, LLC, San Diego, California, United States
πΊπΈClinical Research Atlanta, Stockbridge, Georgia, United States
πΊπΈCotton O'Neil Clinical Research Center, Topeka, Kansas, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers
- Conditions
- Obesity
- Interventions
- Drug: K-757 and K-833Drug: Matching placebo to K-757Drug: Matching placebo to K-757 and matching placebo to K-833Drug: Matching placebo to K-757, open-label sitagliptinDrug: K-757 and open-label sitagliptin
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Kallyope Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05900531
- Locations
- πΊπΈ
ProSciento, Inc., Chula Vista, California, United States
- Prev
- 1
- 2
- Next